Indication · parkinson's disease

parkinson's disease FDA approvals, PDUFA dates and pipeline.

Updated Snapshot 20261116T222116ZBuilt

We track 4 parkinson's disease drugs. No FDA approvals recorded yet.

Drugs

DrugSponsorModalityDesignations
ARV-102ARVN——
envudeucitinib (ESK-001)ALMSsmall_molecule—
rexaceractGANX——
Juvmo (tavapadon)ABBV——

Upcoming catalysts

DateDrugCompanyEventIndicationStatusSource
2026Year disclosedARV-102ARVNInterim readoutParkinson's diseaseScheduledSEC Form 8-K
1H 2027Half-year disclosedenvudeucitinib (ESK-001)ALMSTrial startParkinson's diseaseScheduledSEC 8-K Exhibit 99.1
Q1 2027Quarter disclosedrexaceractGANXTrial startParkinson's diseaseScheduledSEC 8-K Exhibit 99.1

Past catalysts and decisions

DateDrugCompanyEventIndicationStatusSource
Q3 2026Quarter disclosedrexaceractGANXTrial startParkinson's diseaseScheduledSEC Form 10-Q
October 31, 2025Juvmo (tavapadon)ABBVNDA/BLA submissionParkinson's diseaseCompletedSEC 8-K Exhibit 99.1
February 11, 2025ARV-102ARVNTrial startParkinson's diseaseCompletedSEC 8-K Exhibit 99.1
January 10, 2025ARV-102ARVNTrial startParkinson's diseaseCompletedSEC Form 8-K

All indications · Approval rates by indication

Questions

What parkinson's disease drugs have upcoming PDUFA dates?

None disclosed.

Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.